Different Behavioral Patterns of SARS-COV-2 in Patients with Various Types of Cancers: A Role for Chronic Inflammation Induced by Macrophages

Ehsan Moghanloo  
Tehran University: University of Tehran

Bahman Rahimi-Esboei  
Mazandaran University of Medical Sciences

Habibollah Mahmoodzadeh  
Tehran University of Medical Sciences

Farimah Hadjilooei  
Tehran University of Medical Sciences

Farhad Shahi  
Arak University of Medical Sciences

Sahel Heidari  
Tehran University of Medical Sciences

Bijan Almassian  
Tehran University of Medical Sciences

Research Article

Keywords: SARS-CoV-2, Solid cancer, Hematological cancer, Iran

Posted Date: February 25th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-238224/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

SARS-CoV-2 is a single strand RNA virus that causes ongoing pneumonia-like and severe respiratory disease. This disease is very important in immunosuppressed patients. Since not many studies have been done in people with cancer as high risk group, in this study we examined the different behaviors of this virus in different types of cancer. In this study, patients with a variety of solid and hematologic cancers were screened for SARS-CoV-2. The rates of infection, the rate of mortality, in patients with various cancers, as well as in the families of these patients have been studied. In this study, it was found that the prevalence of SARS-CoV-2 in patients with solid cancers was significantly lower than hematological cancers. Also, the mortality rate in hematological cancers was higher than in solid cancers (P<0.05). Assessments the families of these patients, it was found that patients with solid cancers were also less infected than their family members (P<0.05). Researchers of this study attributed these results to the chronic inflammation and M1 macrophages in these patients. It is essential that additional studies are conducted, especially in terms of biological function.

Introduction

Coronavirus disease of 2019 (COVID-19) is an infectious disease caused by a member of the coronavirus family (single-strand RNA viruses) named SARS-COV-2 that infects humans. It was reported for the first time in Wuhan, China in December 2019 (Surveillances, 2020; Wang et al., 2020b; Zhou et al., 2020) and is currently spreading over more than 150 countries around the world (Tavakoli et al., 2020; Yousefi et al., 2020). SARS-COV-2 causes a broad spectrum of clinical manifestations and most infected people show mild to moderate respiratory symptoms and recover without any special treatment (Bai et al., 2020; Cascella et al., 2020; Recalcati, 2020; Xu et al., 2020; Zhou et al., 2020). But, in high-risk patients with underlying diseases such as diabetes (Gupta et al., 2020), cardiovascular diseases (Chen et al., 2020; Zheng et al., 2020b), cancer (Tian et al., 2020; Wang and Zhang, 2020; Xia et al., 2020), and chronic respiratory diseases (Halpin et al., 2020; Jordan et al., 2020) serious forms of the disease and even in some cases death are observed. The increased human-to-human transmission rate is the main characteristic of the new coronavirus that consequently led to the pandemic spread of COVID-19 (Bai et al., 2020; Kucharski et al., 2020). Transmission of the disease occurs through infected droplets or discharges generated while speaking, sneezing, or coughing by the infected individuals (Qian et al., 2020). Prevention practice is applicable by washing hands, using an alcohol-based rub regularly and not touching the face (Hellewell et al., 2020; Wang et al., 2020a). Although countless clinical trials are ongoing to evaluate the potential efficacy of different treatments in COVID-19 cases, there is no specific therapeutics or vaccines available yet (Cascella et al., 2020; Yousefi et al., 2020). The knowledge regarding lymphocyte subsets and the consequence of immune responses in patients with this disease are very limited. Cancer is considered as a very important risk factor for COVID-19 and based on many previous works; the rate of COVID-19 in patients with cancer has been significantly higher than healthy individuals (Burki, 2020; Cortiula et al., 2020; Liang et al., 2020). Also, most studies suggest that patients with cancer are more prone to develop the new coronavirus disease than others (Wang and Zhang, 2020).
However, our information regarding the incidence and severity of COVID-19 disease in various types of cancer is presently very little and more studies are needed to show the relationship between different types of cancer and incidence of COVID-19. Therefore, this study was designed and conducted to evaluate the incidence of COVID-19 in patients with different types of cancer.

Materials And Methods

Sampling and patients

This retrospective study with the approval number of 99-0213a was carried out on patients with cancer who were referred to the different cancer centers in Tehran, Iran, from November 2019 to May 2020. Hospitalized cancer patients were previously diagnosed by laboratory and imaging techniques. COVID-19 was clinically diagnosed at the first step according to the World Health Organization (WHO) protocols with different manifestations including more common symptoms such as dry cough, fever, tiredness; less common symptoms such as sore throat, diarrhea, conjunctivitis, loss of taste or smell, headache, discoloration of fingers, toes, or skin rash, aches and pains as less common; and serious symptoms such as chest pain or pressure, difficulties in breathing or shortness of breath and loss of speech or movement. Then, patients with symptoms detected through the questionnaire results were checked by lung CT scan and Real-Time PCR tests.

COVID-19 real-time RT-PCR assays

All samples were handled according to laboratory biosafety guidelines of WHO for COVID-19 and RNAs were extracted using a QIAamp viral RNA extraction mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s instructions. 250 µl of each respiratory tract specimen was used for RNA extraction and the extracted RNAs were kept at -80°C until use.

Reverse-transcriptase real-time PCR (RT-PCR) assays for COVID-19 were performed using QuantiNova Probe RT-PCR kit (Qiagen) and a LightCycler system (Roche, Basel, Switzerland). Each RT-PCR reaction that was prepared contained 5 µl of RNA, 12.5 µl of 2× reaction buffer, 1.6 µl of forward and reverse primers at 10 pM concentration (5′-GTGARATGGTCATGTGTGGCGG-3′ (Forward), 5′-CARATGTTAACACTATTAGCATA-3′ (Reverse)), 0.5 µl of probe (5′-CAGGTGGAACCTCATCAGGAGATGC-3′ (Probe in 5-FAM/3′-BHQ format)), 1 µl of 25× enzyme mixture in a final volume of 25 µl. RT-PCR reaction program composed 40 cycles of 10 min at 45°C for reverse transcription, 5 min at 95°C for PCR initial activation, and 45 cycles of 5 s at 95°C and 30 s at 55°C using an ABI 7500 Fast instrument (Thermo Fisher Scientific) (Fang et al., 2020).

Data analysis

The Shapiro-Wilk test was used to assess the normality of the data distribution. All data were analyzed with GraphPad Prism software (GraphPad Software, Inc.) and Fisher’s exact test was used to compare the results. P-value of < 0.05 was considered statistically significant.
Results

In the current study, 571 cancer patients who have been admitted to three designated cancer research centers in Tehran, Iran, from November 2019 to May 2020 were enrolled. Out of 571 patients, 362 (63.39%) and 209 (36.60%) had solid and hematologic malignancies, respectively. With regard to sex, 241 (42.20%) patients were male and 330 (57.79%) were female. Age analysis showed that 106 (18.56%), 263 (46.05%) and 202 (35.37%) of patients were 15–35, 35–55, and > 55 years old, respectively. 309 (54.11%) patients were local residents of Tehran and 262 (45.88%) were from other regions Iran.

The Demographic and baseline clinical characteristics of COVID-19 patients in solid cancers are described in Table 1. Among cancer patients, Breast, Gastric, and Lung cancers were the most prevalent forms of cancer (P < 0.05). Also, most of the patients were in stage I or II of their disease. Based on clinical manifestations, 86.74% (314/362) of patients with solid tumors showed no clinical signs and only 5 (1.38%) patients indicated severe clinical manifestations of COVID-19 that these differences were statistically significant (P < 0.001). Results of the confirmatory tests indicated that 9 (2.48%) patients with different types of solid tumors were positive for COVID-19, whereas, 46 (12.70%) patients had close contact with COVID-19 patients in their family and were closely exposed (Fig. 1).
| Characteristics                      | Patients (n = 362) |
|--------------------------------------|-------------------|
| **Tumor diagnosis**                  |                   |
| Breast Cancer                        | 76 (20.99%)       |
| Lung Cancer                          | 35 (9.66%)        |
| Esophageal Cancer                    | 13 (3.59%)        |
| Head and neck Tumor                  | 29 (8.01%)        |
| Nasopharyngeal Cancer                | 12 (3.31%)        |
| Laryngeal Cancer                     | 11 (3.03%)        |
| Liver Cancer                         | 25 (6.90%)        |
| Gastric Cancer                       | 53 (14.64%)       |
| Prostate Cancer                      | 17 (4.69%)        |
| Cervical Cancer                      | 18 (4.97%)        |
| Uterine Tumor                        | 12 (3.31%)        |
| Ovarian Cancer                       | 12 (3.31%)        |
| Colon Cancer                         | 38 (10.49%)       |
| Rectal Cancer                        | 11 (3.03%)        |
| **Tumor stage**                      |                   |
| Stage I                              | 144 (39.77%)      |
| Stage II                             | 126 (34.80%)      |
| Stage III                            | 67 (18.50%)       |
| Stage IV                             | 25 (6.90%)        |
| **Symptoms and signs at on admission** |               |
| No clinical sign                     | 314 (86.74%)      |
| Mild symptoms                        | 43 (11.87%)       |
| Severe symptoms                      | 5 (1.38%)         |
| **Chemotherapy**                     |                   |
| Before 1–4 weeks                     | 53 (14.64%)       |
| Before 1–6 months                    | 142 (39.22%)      |
| No treatment                         | 167 (46.113%)     |
| **Confirmation tests**               |                   |
| Serology                             | 23 (6.35%)        |
| Real time PCR                        | 116 (32.04%)      |
| chest CT                             | 223 (61.60%)      |
| Characteristics                  | Patients (n = 362) |
|----------------------------------|--------------------|
| COVID-19 result                  |                    |
| Positive                         | 9 (2.48%)          |
| Negative                         | 353 (97.51%)       |
| COVID-19 in patients family      |                    |
| Positive                         | 46 (12.70%)        |
| Negative                         | 316 (87.29%)       |
Table 2
Demographic and baseline clinical characteristics of COVID-19 patients in hematologic malignancies

| Characteristics                      | Patients (n = 209) |
|--------------------------------------|-------------------|
| Tumor diagnosis                      |                   |
| DLBL                                 | 65 (31.10%)       |
| AML                                  | 53 (25.35%)       |
| ALL                                  | 41 (19.61%)       |
| CML                                  | 8 (3.82%)         |
| CLL                                  | 6 (2.87%)         |
| Hodgkin Lymphoma                     | 12 (5.74%)        |
| Granulomatous Lymphoma               | 8 (3.82%)         |
| Kaposi Sarcoma                       | 17 (8.13%)        |
| Tumor stage                          |                   |
| Stage I                              | 235 (64.91%)      |
| Stage II                             | 54 (14.91%)       |
| Stage III                            | 43 (11.87%)       |
| Stage IV                             | 30 (8.28%)        |
| Symptoms and signs at on admission   |                   |
| No clinical sign/death (Excluded)    | 113 (54.06%)      |
| Mild symptoms                        | 55 (26.13%)       |
| Severe symptoms                      | 41 (19.61%)       |
| Chemotherapy                         |                   |
| Before 1–4 weeks                     | 46 (22.00%)       |
| Before 1–6 months                    | 139 (66.50%)      |
| No treatment                         | 24 (11.48%)       |
| COVID-19 result                      |                   |
| Positive                             | 47 (22.48%)       |
| Negative                             | 49 (23.44%)       |
| COVID-19 in patients family          |                   |
| Positive                             | 16 (7.65%)        |
| Negative                             | 80 (38.27)        |

Among different types of malignancies, DLBL (Diffuse large B-cell lymphoma) was the most frequent type (31.10%), followed by AML (25.35%) and ALL cancers (19.61%). The morbidity rate of COVID-19 in hematologic malignancies (54.96%) was significantly higher than the solid tumors (P = 0.004). Also, in patients with hematologic malignancies, the rates of clinical manifestations (mild (26.13%) and severe (19.61%)) were higher in comparison to the solid type.
Most of the patients in both groups of malignancies (hematologic and solid) had a history of antitumor chemotherapy and were divided into two main clusters according to the received treatments: 1) patients with chemotherapy during the last 1–4 weeks, 2) patients with chemotherapy during 1–6 months. Clinical manifestations of these two clusters are shown in Table 3.

| Chemotherapy       | Solid Cancer | Malignancies | P-value |
|--------------------|--------------|--------------|---------|
|                    | Mild signs   | Severe signs | Mild signs | Severe signs |
| Last 1–4 weeks     | 13 (3.59%)  | 2 (0.55%)   | 21 (10.04) | 24 (11.48%) | 0.001 |
| Last 1–6 months    | 19 (5.24%)  | 2 (0.55%)   | 25 (11.96%) | 36 (17.22) | 0.001 |
| P-value            | 0.001        |

Patients with clinical manifestations of COVID-19 who had received chemotherapy during the last 4 weeks were examined using CT-scan and Real-Time PCR tests and our results showed that the sensitivity of the real-time PCR test was significantly higher than the CT-scan.

### Discussion

In the current study, the clinical characteristics of 571 cancer patients (with solid or hematologic cancer) were described. Cancer patients who were referred to the cancer research centers during the past 8 months were primarily examined using a questionnaire. Patients were divided into different clinical categories based on the clinical signs (mild and severe) recorded in the Iranian Coronavirus Control Organization. Patients with clinical symptoms of the new coronavirus disease and chemotherapy in the last 4 weeks were re-examined using confirmatory tests for COVID-19 (CT-scan and Real-Time PCR). Also, all family members of patients with cancer were examined for COVID-19 to determine if the patients were at risk for the disease. The results of our study revealed that the rates of mortality, manifestations, and especially severe manifestations of COVID-19 in hematological malignancies were significantly higher than solid cancers and patients with solid cancers showed more resistance to the disease. Interestingly, patients with solid tumors who had close contact with SARS-COV-2 infected individuals in their families were resistant and not infected. This resistance existed even after chemotherapy. Patients with different types of hematological malignancies showed severe symptoms of the new coronavirus disease after chemotherapy, and some even died. The mortality rate of COVID-19 in the group of solid cancers was much lower and no death was reported. Different behavioral patterns observed in patients with various types of cancers in the face of COVID-19 disease are very important and the researchers of the current study noticed this difference during the last 3 months.

Inflammatory cells play important roles in cancer (Fulop et al., 2020; Grizzi et al., 2020; Tseng et al., 2020). Cancer expansion and development are multifaceted processes that are also regulated by the
surrounding microenvironment generated by the innate and adaptive immune cells such as dendritic cells, T cells, and macrophages (Katz and Rabinovich, 2020; Rezaei et al., 2020). Macrophages are present in all tissues and play imperative roles in the preservation of homeostasis in tissues (Nouwen and Everts, 2020; Wu and Lu, 2020). Macrophages are regularly differentiated from peripheral blood monocytes and categorized into three types, namely, tissue-resident macrophages (TRM), myeloid-derived suppressor cells (MDSC), and tumor-associated macrophages (TAMs) (Beatson et al., 2020; Etzerodt et al., 2020; Gross-Vered et al., 2020; Heideveld et al., 2020; Liu et al., 2020b).

In terms of their function, macrophages are divided into two types; classically activated M1 or good macrophages and alternatively activated M2 subtypes or bad macrophages (Klichinsky et al., 2020). M1 macrophages are presented in T-helper type 1 (Th1) responses that are promoted by Th1 cytokines such as interleukin-12 (IL-12) and IL-18. This type of macrophages generate reactive oxygen/nitrogen species and pro-inflammatory cytokines such as IL-1β, IL-6, tumor necrosis factor α (TNF-α), and are important in innate host defense and killing tumor cells (Zhang et al., 2014; Genin et al., 2015; Chunying Xie, 2020). M2 is another type of macrophages that produces IL-4, IL-10, IL-13, and TGF-β as Th2 cytokines to promote tumor development (Sica et al., 2006; Na et al., 2013; Comito et al., 2014) (Fig. 2).

Cytokine release syndrome (CRS) is a complete response to the inflammation caused by usual infections. Many drugs and other factors have been designed to induce the production of a large amount of pro-inflammatory cytokines and increase the strength of the immune system (Hirano and Murakami, 2020). CRS is commonly happening during immune system-related diseases or immune-related therapies and also in infectious diseases such as viral infections (Hirano and Murakami, 2020; Liu et al., 2020a). IFN-γ is one of the most important functional cytokines which plays an important role in defense against intracellular pathogens and also cancers (Liu et al., 2020a; Mehta et al., 2020; Zheng et al., 2020a). The results of various studies have shown that the levels of pre-inflammatory cytokines and IFN-γ in patients with solid cancers are naturally elevated (Gaire et al., 2020; Zhang et al., 2020). The study conducted by Qing et al (2020) reported that the levels of IL-1B, IFN-γ, IP-10, and monocyte chemoattractant protein 1 (MCP-1) in patients with COVID-19 was significantly high. These cytokines are Th1 activators and are key factors for the activation of specific immunity and unfortunately are positively correlated with the severity of COVID-19 (Ye et al., 2020).

CRS and cytokine storms have shown a direct association with COVID-19 in acute inflammations, but the behavior of the disease in chronic inflammations is completely different. In chronic inflammations, the interaction between macrophages and solid tumors leads to the production of IFN-γ by M1 TAMs. The high levels of IFN-γ in chronic inflammations result in the resistance of the patients with solid tumors to COVID-19 in comparison to the patients with hematologic malignancies. In a comparable study, many studies revealed that vaccinations with BCG vaccine cause chronic and non-specific immunity that surprisingly decreases the incidence and mortality of COVID-19 (Bodova et al., 2020; O'Neill and Netea, 2020).
One of the important aspects of this study, which is different from other investigations, is the survey of family and people who are in contact with the patient. Our study and other similar studies have shown that many people with no clinical symptoms were molecularly positive. These people are carriers and can transmit the disease.

The importance of this group (asymptomatic carriers) will be much greater if they are in contact with cancer patients. Chemotherapy weakens the immune system and increases the risk of developing the disease. Researchers are concerned about the presence of asymptomatic carriers in contact with candidates for chemotherapy. Therefore, it is recommended that either all patients await chemotherapy and families and individuals in contact with them undergo a molecular analysis prior to chemotherapy, or chemotherapy is performed under hygienic and supervised measures.

In this study, the incidence rate of COVID-19 in patients with cancer was investigated. Two groups of patients were studied, including patients with solid cancer and patients with hematological malignancies. The results showed that COVID-19 was much less common in patients with solid cancers in comparison to patients with hematological malignancies. Even in cases that family members of patients were infected with COVID-19, patients with solid tumors were not infected. Researchers of this study attributed these results to the chronic inflammation and M1 macrophages in these patients. Due to the importance of COVID-19 and cancer in the world and based on the results of this study, it is essential that additional studies are conducted, especially in terms of biological function. Finally, researchers of this study invite other researchers from all research centers around the world to cooperate and participate in further supplementary studies.

**Declarations**

**Ethics approval and consent to participate**

This study is ethically approved by Ethics committee of Tehran University of Medical Sciences with the code of: IR.TUMS.VCR.REC.1397.866 and Required coordination with Hospital Cancer clinics was made to provide the patients with the questionnaires.

**Consent for publication**

All of our co-authors are agreement for publication.

**Data availability**

The data is held by the Imam Khomeini hospital, and access to the data can be requested and authorized by the Cancer research center group. Which, at the time of the high prevalence of Covid-19, it was the first diagnostic and treatment center and is still the reference center in Iran.

**Availability of data and material**
All data of the patients unless name and other private information are sent to journal as supplementary files.

**Competing interests**

There are not any conflicts of interest.

**Funding**

This study was supported by the Cancer research center in Imam Khomeini hospital, Tehran University of Medical Sciences (TUMS).

**Author contributions**

EM. Hypotheses, E.M., B.R.E. and H.M. designed and do most of the experiments, B.R.E., F.H and B.A contributed to sample selection, E.M., B.R.E and S.H. performed the analysis of data, B.R.E. and E.M write the draft and the draft is reviewed by K.W. and H.M.

**Acknowledgment**

The authors would like to express their deep thanks to Prof. Mahmoodzadeh for her support to our hypothesis and key suggestions. And special thanks to Prof. Wang from Department of Immunology, School of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA for scientific edition.

**References**

Bai, Y., Yao, L., Wei, T., Tian, F., Jin, D.-Y., Chen, L., Wang, M., 2020. Presumed asymptomatic carrier transmission of COVID-19. Jama 323, 1406-1407.

Beatson, R., Graham, R., Freile, F.G., Cozzetto, D., Kannambath, S., Pfeifer, E., Woodman, N., Owen, J., Nuamah, R., Mandel, U., 2020. Cancer-associated hypersialylated MUC1 drives the differentiation of monocytes into macrophages with a pathogenic phenotype. bioRxiv.

Bodova, K., Boza, V., Brejova, B., Kollar, R., Mikusova, K., Vinar, T., 2020. Time-adjusted Analysis Shows Weak Associations Between BCG Vaccination Policy and COVID-19 Disease Progression. medRxiv.

Burki, T.K., 2020. Cancer guidelines during the COVID-19 pandemic. The Lancet Oncology 21, 629-630.

Cascella, M., Rajnik, M., Cuomo, A., Dulebohn, S.C., Di Napoli, R., 2020. Features, evaluation and treatment coronavirus (COVID-19). Statpearls [internet]. StatPearls Publishing.

Chen, C., Yan, J., Zhou, N., Zhao, J., Wang, D., 2020. Analysis of myocardial injury in patients with COVID-19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua xin xue guan bing za zhi 48, E008-E008.
Chunying Xie, Y.G.S.L., 2020. LncRNA ANCR Promotes Invasion and Migration of Gastric Cancer by Regulating FoxO1 Expression to Inhibit Macrophage M1 Polarization. Digestive Diseases and Sciences 1, 6-13.

Comito, G., Giannoni, E., Segura, C., Barcellos-de-Souza, P., Raspolini, M., Baroni, G., Lanciotti, M., Serni, S., Chiarugi, P., 2014. Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression. Oncogene 33, 2423-2431.

Cortiula, F., Pettke, A., Bartoletti, M., Puglisi, F., Helleday, T., 2020. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Annals of Oncology 31, 553.

Etzerodt, A., Moulin, M., Doktor, T.K., Delfini, M., Mossadegh-Keller, N., Bajenoff, M., Sieweke, M.H., Moestrup, S.K., Auphan-Anezin, N., Lawrence, T., 2020. Tissue-resident macrophages in omentum promote metastatic spread of ovarian cancer. The Journal of Experimental Medicine 217.

Fang, Y., Zhang, H., Xie, J., Lin, M., Ying, L., Pang, P., Ji, W., 2020. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology, 200432.

Fulop, T., Pawelec, G., Dupuis, G., Kotb, R., Friguet, B., Witkowski, J.M., Larbi, A., 2020. Immunosenescence, oxidative stress, and cancers. Cancer Immunology. Springer, pp. 513-531.

Gaire, B., Uddin, M.M., Zou, Y., Vancurova, I., 2020. Analysis of IFNγ-Induced Migration of Ovarian Cancer Cells. Immune Mediators in Cancer. Springer, pp. 101-106.

Genin, M., Clement, F., Fattaccioli, A., Raes, M., Michiels, C., 2015. M1 and M2 macrophages derived from THP-1 cells differentially modulate the response of cancer cells to etoposide. BMC cancer 15, 577.

Grizzi, F., Borroni, E.M., Yiu, D., Farina, F.M., Cananzi, F.C.M., Laghi, L., 2020. Prognostic Value of Innate and Adaptive Immunity in Cancers. Cancer Immunology. Springer, pp. 403-415.

Gross-Vered, M., Trzebanski, S., Shemer, A., Bernshtein, B., Curato, C., Stelzer, G., Salame, T.-M., David, E., Boura-Halfon, S., Chappell-Maor, L., 2020. Defining murine monocyte differentiation into colonic and ileal macrophages. eLife 9.

Gupta, R., Ghosh, A., Singh, A.K., Misra, A., 2020. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes & metabolic syndrome 14, 211.

Halpin, D.M., Faner, R., Sibila, O., Badia, J.R., Agusti, A., 2020. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? The Lancet Respiratory Medicine 8, 436-438.

Heideveld, E., Horcas-Lopez, M., Lopez-Yrigoyen, M., Forrester, L.M., Cassetta, L., Pollard, J.W., 2020. Methods for macrophage differentiation and in vitro generation of human tumor associated-like macrophages. Methods in Enzymology. Elsevier, pp. 113-131.
Hellewell, J., Abbott, S., Gimma, A., Bosse, N.I., Jarvis, C.I., Russell, T.W., Munday, J.D., Kucharski, A.J., Edmunds, W.J., Sun, F., 2020. Feasibility of controlling COVID-19 outbreaks by isolation of cases and contacts. The Lancet Global Health.

Hirano, T., Murakami, M., 2020. COVID-19: A new virus, but a familiar receptor and cytokine release syndrome. Immunity.

Jordan, R.E., Adab, P., Cheng, K., 2020. Covid-19: risk factors for severe disease and death. British Medical Journal Publishing Group.

Katz, S.G., Rabinovich, P.M., 2020. T Cell Reprogramming Against Cancer. Cell Reprogramming for Immunotherapy. Springer, pp. 3-44.

Klichinsky, M., Ruella, M., Shestova, O., Lu, X.M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N.R., Petty, N.E., 2020. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nature Biotechnology, 1-7.

Kucharski, A.J., Russell, T.W., Diamond, C., Liu, Y., Edmunds, J., Funk, S., Eggo, R.M., Sun, F., Jit, M., Munday, J.D., 2020. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The lancet infectious diseases.

Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., Li, C., Ai, Q., Lu, W., Liang, H., 2020. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology 21, 335-337.

Liu, B., Li, M., Zhou, Z., Guan, X., Xiang, Y., 2020a. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Journal of Autoimmunity, 102452.

Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., Wang, X., 2020b. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages. Cancer Letters 469, 173-185.

Mehta, P., McAuley, D.F., Brown, M., Sanchez, E., Tattersall, R.S., Manson, J.J., 2020. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet 395, 1033-1034.

Na, Y.-R., Yoon, Y.-N., Son, D.-I., Seok, S.-H., 2013. Cyclooxygenase-2 inhibition blocks M2 macrophage differentiation and suppresses metastasis in murine breast cancer model. PloS one 8.

Nouwen, L.V., Everts, B., 2020. Pathogens MenTORing Macrophages and Dendritic Cells: Manipulation of mTOR and Cellular Metabolism to Promote Immune Escape. Cells 9, 161.

O’Neill, L.A., Netea, M.G., 2020. BCG-induced trained immunity: can it offer protection against COVID-19? Nature Reviews Immunology, 1-3.
Qian, G., Yang, N., Ma, A.H.Y., Wang, L., Li, G., Chen, X., Chen, X., 2020. COVID-19 Transmission Within a Family Cluster by Presymptomatic Carriers in China. Clinical Infectious Diseases.

Recalcati, S., 2020. Cutaneous manifestations in COVID-19: a first perspective. Journal of the European Academy of Dermatology and Venereology.

Rezaei, N., Aalaei-Andabili, S.H., Amini, N., Delavari, F., Keshavarz-Fathi, M., Kaufman, H.L., 2020. Introduction on cancer immunology and immunotherapy. Cancer immunology. Springer, pp. 1-9.

Sica, A., Schioppa, T., Mantovani, A., Allavena, P., 2006. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. European journal of cancer 42, 717-727.

Surveillances, V., 2020. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)—China, 2020. China CDC Weekly 2, 113-122.

Tavakoli, A., Vahdat, K., Keshavarz, M., 2020. Novel coronavirus disease 2019 (COVID-19): an emerging infectious disease in the 21st century. ISMJ 22, 432-450.

Tian, S., Hu, W., Niu, L., Liu, H., Xu, H., Xiao, S.-Y., 2020. Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. Journal of Thoracic Oncology.

Tseng, D., Schultz, L., Pardoll, D., Mackall, C., 2020. Cancer Immunology. Abeloff's Clinical Oncology. Elsevier, pp. 84-96. e85.

Wang, H., Zhang, L., 2020. Risk of COVID-19 for patients with cancer. The Lancet Oncology 21, e181.

Wang, J., Tang, K., Feng, K., Lv, W., 2020a. High temperature and high humidity reduce the transmission of COVID-19. Available at SSRN 3551767.

Wang, S., Guo, L., Chen, L., Liu, W., Cao, Y., Zhang, J., Feng, L., 2020b. A case report of neonatal COVID-19 infection in China. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America.

Wu, M.-Y., Lu, J.-H., 2020. Autophagy and Macrophage Functions: Inflammatory Response and Phagocytosis. Cells 9, 70.

Xia, Y., Jin, R., Zhao, J., Li, W., Shen, H., 2020. Risk of COVID-19 for patients with cancer. The Lancet Oncology 21, e180.

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., 2020. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet respiratory medicine 8, 420-422.
Ye, Q., Wang, B., Mao, J., 2020. The pathogenesis and treatment of the Cytokine Storm in COVID-19. The Journal of Infection.

Yousefi, B., Valizadeh, S., Ghaffari, H., Vahedi, A., Karbalaei, M., Eslami, M., 2020. A global treatments for coronaviruses including COVID-19. Journal of Cellular Physiology.

Zhang, M., He, Y., Sun, X., Li, Q., Wang, W., Zhao, A., Di, W., 2014. A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. Journal of ovarian research 7, 19.

Zhang, M., Huang, L., Ding, G., Huang, H., Cao, G., Sun, X., Lou, N., Wei, Q., Shen, T., Xu, X., 2020. Interferon gamma inhibits CXCL8–CXCR2 axis mediated tumor-associated macrophages tumor trafficking and enhances anti-PD1 efficacy in pancreatic cancer. Journal for immunotherapy of cancer 8.

Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Xu, Y., Tian, Z., 2020a. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & molecular immunology, 1-3.

Zheng, Y.-Y., Ma, Y.-T., Zhang, J.-Y., Xie, X., 2020b. COVID-19 and the cardiovascular system. Nature Reviews Cardiology 17, 259-260.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., 2020. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet.

**Figures**
Figure 1

Results of the confirmatory tests indicated that 9 (2.48%) patients with different types of solid tumors were positive for COVID-19, whereas, 46 (12.70%) patients had close contact with COVID-19 patients in their family and were closely exposed.
Figure 2

M2 is another type of macrophages that produces IL-4, IL-10, IL-13, and TGF-β as Th2 cytokines to promote tumor development (Sica et al., 2006; Na et al., 2013; Comito et al., 2014)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- PatientsDATAforCOVID19.docx